Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major
- In the first phase of the study we will develop a panel of reagents designed to
identify predominant thalassemia mutations in the Iranian population, as well as
alternative highly variable erythroid specific polymorphisms. To determine how
informative this panel is, these reagents will be applied to samples collected from
patients homozygous for the disorder, and compared to patients with thalassemia trait
and normal Iranian donors.
- In the second phase, we propose to serially measure and compare erythroid lineage
chimerism with overall genomic chimerism following transplant. Samples will be
collected from participants before and at 1, 2, 3, 6 and 12 months following transplant
and cryopreserved. Peripheral blood from the stem cell donor will also be collected
and cryopreserved. Participants will undergo myeloablative or nonmyeloablative
transplant.
Observational
Time Perspective: Retrospective
Catherine Wu, MD
Principal Investigator
Dana-Farber Cancer Institute
United States: Institutional Review Board
04-078
NCT00480506
April 2004
October 2005
Name | Location |
---|---|
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |